In the midst of the excitement surrounding CAR T therapies, much needs to be done to optimize CAR T cell efficacy. 2017 AACR Next Gen Grant Recipient Sidi Chen, PhD leveraged in vivo genome engineering methods and identified a new target to do just that.
PanCAN-AACR Grantee Shows Potential Dual Anti-cancer and Anti-cachexia Benefits of Targeting Perp in Pancreatic Cancer
Cachexia is a muscle-wasting syndrome that is commonly found in pancreatic and other cancer patients. A group led by 2017 Pancreatic Cancer Action Network-AACR Career Development Award recipient Jason D. Doles, PhD, identified Perp as a novel tumor promoter and mediator of cancer-associated muscle wasting.
2019 AACR-Amgen Fellow, Julia Frede, PhD, reported in Nature Cell Biology, how treatment can induce the expression of a distinct set of actionable immunotherapy targets in multiple myeloma, such as CXCR4, which can be exploited to keep treatment resistance at bay.
AACR-AstraZeneca Immuno-Oncology Fellow Uncovers a Role for Tissue-Resident Macrophages in Early Lung Cancer Development
2020 AACR-AstraZeneca Immuno-Oncology Fellow, Maria Casanova-Acebes, PhD, now current head of the Cancer Immunity Group at the Spanish National Cancer Research Centre (CNIO), reported in Nature their findings on how tissue-resident macrophages may influence lung cancer development.
AACR-Incyte Immuno-Oncology Fellow Shows Therapeutic Potential of Targeting TCR Signaling Phosphatase PTPN22
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) has been primarily studied in the context of autoimmune diseases. 2019 AACR-InCyte Immuno-oncology Fellow Won Jin Ho, MD, showed how PTPN22 inhibition retards tumor growth in a T-cell- and macrophage-dependent manner.
More than half of melanomas contain extra copies of the sirtuin 5 gene. Two AACR-Bayer Innovation and Discovery grant recipients and an AACR NextGen Grant recipient, along with their colleagues, demonstrated that sirtuin 5 is required for melanoma cell proliferation and survival.
2015 Kure It-AACR Grantee Investigates Mechanisms of Immune Checkpoint Blockade Resistance in Renal Cell Carcinoma
A team of investigators led by 2015 KureIt-AACR Grantee Dr. Eliezer Van Allen and Dr. Toni Choueiri probed the changes in the tumor and immune system in advanced renal cell carcinoma patients who received immune check point blockade (ICB).
For a second year in a row, the Global Scholar-in-Training Award (GSITA) program will welcome early-career researchers from around the world to a virtual American Association for Cancer Research Annual Meeting. In an ordinary year, the GSITA program provides...
AACR-AstraZeneca Lung Cancer Fellow Shows How Blocking an Arginine Methyltransferase Can Overcome Immunotherapy Resistance
2018 AACR-AstraZeneca Lung Cancer Fellow Sushil Kumar demonstrated how inhibition of an epigenetic regulator, arginine methyltransferase CARM1, resulted not only in enhanced anti-tumor activity of T cells but also increased susceptibility of tumor cells to T cell-mediated killing.